Background: Obesity is associated with knee pain and is an independent predictor of incident knee osteoarthritis (OA); increased pain with movement often leads patients to adopt sedentary lifestyles to avoid pain. Detailed descriptions of pain management strategies by body mass index (BMI) level among OA patients are lacking. The objectives were to describe complementary and alternative medicine (CAM) and conventional medication use by BMI level and identify correlates of CAM use by BMI level.
Background
Obesity is an independent predictor of incident knee osteoarthritis (OA) [1] . Both weight gain and malalignment are also associated with increased pain and functional loss [2] . OA patients with body mass index (BMI) ≥ 35 kg/m 2 often experience increased pain due to significant increases in joint stress and load forces on the knees [3] . Obesity is a modifiable risk factor for the development and treatment of knee pain [4] . In two major trials [5, 6] , people randomized to intensive lifestyle interventions which focused on exercise and weight loss demonstrated improvements in pain and physical function relative to controls. Interventions including both exercise and weight loss were more successful than those using either approach alone [7] .
Diffusing interventions is challenging because increased pain with movement often leads patients to adopt sedentary lifestyles to avoid pain, which leads to more weight gain, pain, and disability.
OA is a chronic disease with no cure so patients often treat pain with conventional medications or therapies [8] and complementary and alternative medicines (CAM) [9, 10] . Glucosamine [11] and acupuncture [12] do relieve symptoms among OA patients. Obese adults are less likely to use CAM overall [13] , but detailed CAM practices among people with higher BMI are unknown.
The Osteoarthritis Initiative (OAI) provides the opportunity to address this gap in the literature. The OAI is a multi-center, prospective observational study which examines the natural history of and identifies risk factors for incidence and progression of knee OA [14] . The OAI is a unique data source because it provides a population with radiographic confirmation of OA and detailed assessments of knee-specific pain, quality of life, and functioning indicators using standardized instruments. The study purpose was twofold: 1) to describe differences in treatment approaches to manage symptoms of knee OA by level of BMI; and 2) to evaluate the extent to which sociodemographic and clinical correlates of CAM use differed by BMI.
Methods
The University of Massachusetts Medical School Institutional Review Board reviewed and approved the protocol for this study. Because publicly-available data were used for this study, the Institutional Review Board waived the need for documentation of informed consent from participants.
We used publicly available data from the OAI (http:// www.oai.ucsf.edu/) (#AllClinical00, V0.2.2). The OAI began recruiting in 2004 and engaged 4,796 participants aged 45 to 79 years. At baseline, each participant underwent 3.0 Tesla MRI examinations of the knee and provided blood samples, and each clinical site had readers (trained through didactic and interactive webbased methods) assess fixed flexion knee x-rays for osteophytes and joint space narrowing. Eligibility was restricted to those without severe joint space narrowing in both knees. The participants were followed annually for the development or progression of knee OA. We included 2,679 individuals with radiographic tibiofemoral knee OA (e.g. OARSI atlas osteophyte grade I-III) [15] in at least one knee at baseline and excluded 4 participants with missing height and/or weight measured using standardized methods (n = 2,675). Participants were classified into four categories: BMI less than 25 kg/m 2 , BMI between 25 and less than 30 kg/m 2 (overweight), BMI from 30 to less than 35 kg/m 2 (obese), and BMI of at least 35 kg/m 2 (severe obesity) [16] .
Classification of use of CAM and conventional medications
Complementary and alternative therapies were defined as [9] : 1) alternative medical systems (e.g. homeopathy, acupuncture); 2) mind-body interventions (e.g. pilates, spiritual activities, relaxation therapy); 3) manipulation [24, 25] indicated the worst pain (range 0 to 20). Knee-related quality of life was measured by the Knee injury and Osteoarthritis Outcome Score (KOOS) by calculating a summary score ranging from 0 to 100 (range: 0 (extreme symptoms) to 100 (no symptoms)) [26] . The knee with worse measures was used in the analysis. Walking ability and endurance were measured by a 20-meter walk, averaged over two trials [27] . The chair stand test directly assessed leg strength and knee function and duration of time (seconds) needed to stand up and sit down five times as quickly as possible [28] .
Participants were classified by x-ray joint space narrowing as determined by OARSI atlas grade on a fixed flexion radiograph of the knee with the worst measure. Multiple-joint OA symptoms were measured with selfreported information at baseline: low back pain in previous 30 days, OA in hand, hip symptoms, and hip replacement. Information on previous history of knee injury or surgery was also collected.
Analytic approach
A multivariable multinomial logistic regression model was developed to estimate the association between BMI level and CAM/conventional treatment use after adjusting Figure 1 shows CAM use and types of concurrent conventional medication use by BMI level. The most commonly used concurrent conventional therapies amongst all BMI groups was acetaminophen and/or non-steroidal anti-inflammatory agents (NSAIDs) which were over-thecounter or prescription. 
Discussion
Persons with BMI levels of at least 25 kg/m 2 had greater prevalence of severe joint space narrowing, greater pain, and reduced quality of life relative to persons with BMI < 25 kg/m 2 . Despite a greater disease burden among persons with BMI ≥ 25 kg/m 2 , we observed less CAM use and greater conventional medication use relative to those with BMI < 25 kg/m 2 . Our study was consistent with general population studies in that use of individual CAM modalities were less common in those with higher BMI levels, albeit differences were modest [13] . Chiropractic use did not differ substantially by levels of BMI, which was not consistent with studies showing less chiropractic use among obese persons [29] . Considering all individual CAM modalities, CAM use, either alone or in conjunction with conventional medications, was less common among persons with higher BMI levels. We acknowledge that the clinical relevance of some of the observed differences is unclear.
The correlates of CAM use differed by BMI level for some, but not all factors. Women were more likely to report use of CAM for knee OA than men and quality of life was inversely associated with CAM use. Age of at least 65 years was associated with CAM use only among those with BMI ≥ 35 kg/m 2 . Black participants tended to have lower odds of CAM use relative to white participants among those with BMI between 25 and <30 kg/m 2 . This association was not evident among other BMI levels. Our finding that black participants had reduced odds of use of CAM therapies than white participants was consistent with some previous studies [30] . The reasons for racial differences in CAM use are likely multifactorial, including different access to health care and socioeconomic positioning. In our study, black participants had less favorable socioeconomic positioning relative to white participants. Residual confounding from socioeconomic status may partially explain the inverse association. The reasons for inconsistent association between race and CAM use across BMI levels are unclear. Among persons with BMI < 25 kg/m 2 , depression was inversely associated with CAM use. We are unable to evaluate the extent to which these findings are consistent with the literature because, to our knowledge, no BMI level-specific correlates of CAM use have been published.
Given there is no cure for OA, the clinical implications of these findings must be considered. The use of CAM to slow disease progression is not supported by research, yet symptom relief among OA patients has been reported with glucosamine [11] and acupuncture [12] . Obesity is a modifiable risk factor for the development and treatment of knee pain [4] . Indeed, evidence from trials [5] [6] [7] suggests that intensive exercise and weight loss interventions result in improved pain and physical function measures. However, the beneficial effects of weight loss may be challenged by joint damage and chronic pain from OA, which cause muscle atrophy, decreased mobility, poor balance, and eventual physical disability [4] . Some researchers have suggested that adoption of weight loss strategies may be hampered by pain, and that intensive treatment of pain resulting from knee OA may improve exercise capacity and quality of life [4] .
The reasons why use of the treatment options is less among persons with higher BMI levels are likely multifactorial, and may include differences in patient preference, knowledge, and access to CAM. As the OAI did not collect such information, we were unable to explore the extent to which these factors explained observed differences. Reports show CAM users in general pursue generally healthy lifestyles [31] , but use of CAM for weight loss remains relatively low [32] . The latter finding may suggest that persons with higher BMI levels may be reluctant to use CAM in general, rather than reluctant to use CAM specifically for OA symptom relief.
This study has several important limitations to consider. The data shown are cross-sectional. The temporal sequence of symptoms and treatment cannot be determined from this design. Data regarding symptoms and treatment are based on self-report and may have introduced bias. However, the information regarding conventional medications and CAM therapies are based on either a 30-day or 6-month recall. We believe this type of misclassification is likely minimal and non-differential with respect to BMI levels. Thus, if any distortions were introduced, they would have attenuated the observed associations. We are unable to comment on the extent to which patterns of CAM use by BMI levels indicate overuse of CAM by persons with lower BMI level or underuse of CAM by persons with higher BMI levels.
Conclusion
Our study suggests that despite increased burden of disease, overweight and obese patients with radiographicallyconfirmed knee OA are using CAM therapies less often than those with lower BMI levels, but use of conventional medications are more common in overweight and obese patients. Overweight and obese adults may be less likely to use effective CAM therapies relative to persons with BMI < 25 mg/k 2 . Further research is needed to improve our understanding of the role of CAM in the treatment of knee OA among overweight and obese persons. 
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